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Despite various developments in many fields 
of ophthalmology, the surgical therapy of 
open-angle glaucoma has remained mostly 
unchanged over the last 30 years. Ever since 
the introduction of intraoperative mitomycin 
and postoperative subconjunctival injections 
of 5-fluorouracil (5-FU), trabeculectomy has 
not markedly been altered. These facts stand 
in contrast to the need for a more efficient 
surgical therapy for open-angle glaucoma, 
since one of the main disadvantages of filtering 
surgery is the lack of enduring success. Large-
scale retrospective studies have suggested 
that filtering blebs become non-functional in 
at least 50% of patients, 5 years after surgery. 
This clearly demonstrates the necessity for 
developing techniques to reduce postoperative 
scarring in filtering blebs.
In the current issue of Journal of 
Ophthalmic and Vision Research, Pakravan 
and colleagues1 have examined the effect 
of postoperative topical mitomycin 0.02% 
eye drops on the success of trabeculectomy 
surgery and compared the results with that 
of repeated postoperative subconjunctival 
5-FU injections. In their randomized study, 
for which the authors have to be commended, 
the authors found that topical mitomycin 
compared favorably with subconjunctival 
5-FU injections. Since eye drops are easier to 
apply and cause less pain, topical application 
of mitomycin appears to be a valid alternative 
to subconjunctival 5-FU injections in the 
postoperative period.
Certain questions however remain. First, 
interestingly, the toxicity of mitomycin applied 
topically on intact conjunctival epithelium is 
considerably less than that applied on bare 
sclera. Future studies may address whether 
this disparity is due to different durations of 
application (drops have relatively short period 
of contact with the ocular surface), variations 
in effective concentrations of the agent (drops 
may be diluted by tears), and/or due to the 
protective effect of an intact conjunctival 
epithelium. Second, it is not clear yet whether 
prolonged topical application of mitomycin may 
cause corneal stem cell insufficiency leading 
to problems in corneal epithelialization or 
dry eye due to damage to conjunctival goblet 
cells. Third, the risk of systemic side effects 
of mitomycin eye drops due to absorption 
through the nasolacrimal duct mucosa may 
additionally be addressed.
In conclusion, the study by Pakravan et al 
may show new possibilities and open up a new 
avenue in the postoperative care of patients after 
routine trabeculectomy. Since the application 
of mitomycin eye drops is considerably more 
convenient and probably less costly, it may 
indeed be an alternative to postoperative 
subconjunctival injections of 5-FU.
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